Is There Evidence to Support Kombucha Health Claims in Humans?
According to the results of a systematic review, there is a lack of evidence supporting the potential health benefits of kombucha, a fermented tea beverage, in humans.
Miscellaneous Immune Disorders
Asceniv Approved for Primary Humoral Immunodeficiency in Adolescents, Adults
ADMA Biologics announced that the FDA has approved Asceniv (immune globulin intravenous [human] – slra) 10% Liquid for the treatment of primary humoral immunodeficiency disease (PIDD) in patients aged ≥12 years.
Investigational Treatment for Farber Disease Gets Fast Track, Rare Pediatric Disease Designations
Enzyvant announced that the Food and Drug Administration (FDA) has granted RVT-801 both Rare Pediatric Disease and Fast Track designations for Farber disease.
New Drug Product: Firdapse
This slideshow reviews drug information for Firdapse. Click here for the complete Firdapse monograph.
Report Details Case of Hydrochlorothiazide-Induced Lupus
Based on our finding, hydrochlorothiazide should be considered a possible offending agent when a patient presents with symptoms suspicious of drug induced lupus,” the study authors concluded.
Baricitinib Gets Fast Track Status for Systemic Lupus Erythematosus
Data from a Phase 2 trial of baricitinib for the treatment of SLE supporting the Fast Track designation were published in The Lancet and presented at the European Congress of Rheumatology earlier this year.
Opioid Use High in Patients With Systemic Lupus Erythematosus
Patients with SLE who experienced high pain levels and had a visit to the emergency department the previous year were more likely to use opioids.
Jakafi Granted Priority Review for Acute Graft-Versus-Host Disease
The sNDA included data from the REACH1 study (N=71) which evaluated ruxolitinib in combination with corticosteroids in patients with steroid-refractory acute GVHD.
Researchers Debate Hydroxychloroquine Dosing in SLE
Experts at the 2018 ACR/ARHP Annual Meeting discuss whether hydroxychloroquine dosing should be more than 5 mg/kg in patients with systemic lupus erythematosus.
Rituxan Labeling Updated With Follow Up Treatment Info for Patients With GPA/MPA
The approval for follow up treatment was based on data from an open-label, prospective, active-controlled study (MAINRITSAN) involving 115 patients in disease remission (86 with GPA, 24 with MPA, 5 with renal-limited ANCA-associated vasculitis)
